Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19564653 | 1.00 | SLC6A2 (0.71) | SLC6A2CACNA2D1 | |
| SCHEMBL19552898 | 1.00 | SLC6A2 (0.71) | SLC6A2CACNA2D1 | |
| SCHEMBL21770738 | 0.93 | CACNA2D1 (0.61) | SLC6A2CACNA2D1 | |
| SCHEMBL19553027 | 0.92 | SLC6A2 (0.77) | SLC6A2CACNA2D1 | |
| SCHEMBL19553025 | 0.92 | SLC6A2 (0.77) | SLC6A2CACNA2D1 | |
| SCHEMBL19553438 | 0.92 | SLC6A2 (0.77) | SLC6A2CACNA2D1 | |
| SCHEMBL21770736 | 0.92 | CACNA2D1 (0.60) | SLC6A2CACNA2D1 | |
| SCHEMBL19564664 | 0.91 | CACNA2D1 (0.70) | SLC6A2CACNA2D1 | |
| SCHEMBL21770642 | 0.91 | SLC6A2 (0.64) | SLC6A2CACNA2D1 | |
| SCHEMBL19564666 | 0.91 | CACNA2D1 (0.70) | SLC6A2CACNA2D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190144455-A1 | TETRAHYDROPYRIMIDODIAZEPINE AND DIHYDROPYRIDODIAZEPINE COMPOUNDS FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-05-16 | — | — | US | disclosed |
| WO-2017191304-A1 | TETRAHYDROPYRIMIDODIAZEPINE AND TETRAHYDROPYRIDODIAZEPINE COMPOUNDS FOR TREATING PAIN AND PAIN RELATED CONDITIONS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144455-A1 | TETRAHYDROPYRIMIDODIAZEPINE AND DIHYDROPYRIDODIAZEPINE COMPOUNDS FOR TREATING PAIN AND PAIN RELATED CONDITIONS | CACNA1G, CACNA1B, CACNA1D | SLC6A2 83/4885CACNA2D1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.